This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Impact of Fecal Blood Testing

David A. Ahlquist, MD; George G. Klee, MD, PhD; Douglas B. McGill, MD; Ralph D. Ellefson, PhD

Arch Intern Med. 1990;150(5):1041-1045.

Abstract
• To assess the contribution of fecal blood testing to cancer detection in a clinical practice setting, we studied records from 160 patients with both a new tissue diagnosis of colorectal adenocarcinoma and a preceding stool blood test (HemoQuant, Mayo Medical Laboratories, Rochester, Minn) determination. In this group, 71% had suggestive colorectal symptoms (particularly stool changes, overt bleeding, and abdominal pain) or anemia at presentation, and 29% were asymptomatic. Fecal blood levels remained normal in more than 40% of both symptomatic and asymptomatic patients. In only 26 patients (16% overall) was an abnormal fecal blood level the sole heralding feature, but this subset of patients had a more favorable stage. Fecal blood levels were higher with advanced, larger, and more proximal tumors and with stools collected before purgation. We conclude that, in the practice setting, fecal blood level elevation alone is an uncommon but important manner of colorectal cancer presentation, most cancers present with symptoms, and fecal blood levels are often normal in both symptomatic and asymptomatic patients.

(Arch Intern Med. 1990;150:1041-1045)

Author Affiliations
From the Division of Gastroenterology and Laboratory Medicine, Mayo Clinic, Rochester, Minn.

Footnotes
Accepted for publication December 7,1989.

Reprint requests to Division of Gastroenterology and Laboratory Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Ahlquist).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

DNA Integrity as a Potential Marker for Stool-based Detection of Colorectal Cancer
Boynton et al.
Clin. Chem. 2003;49:1058-1065.
ABSTRACT | FULL TEXT  

Analysis of Colorectal Cancer Stage Among HMO Members Targeted for Screening
Myers et al.
Arch Intern Med 1997;157:2001-2006.
ABSTRACT  

Fecal Occult Blood Screening for Colorectal Cancer
Van Dam et al.
Arch Intern Med 1995;155:2389-2402.
ABSTRACT  

A Comparative Study of Eight Fecal Occult Blood Tests and HemoQuant in Patients in Whom Colonoscopy Is Indicated
Gopalswamy et al.
Arch Fam Med 1994;3:1043-1048.
ABSTRACT  

Comparison of the Specificity and Sensitivity of Hemoccult and HemoQuant in Screening for Colorectal Neoplasia
St. John et al.
ANN INTERN MED 1992;117:376-382.
ABSTRACT  

Diagnostic Yield of a Positive Fecal Occult Blood Test Found on Digital Rectal Examination: Does the Finger Count?
Eisner and Lewis
Arch Intern Med 1991;151:2180-2184.
ABSTRACT  

Limitations of Fecal Occult Blood Testing
SAMPLINER
Arch Intern Med 1990;150:945-946.
ABSTRACT